Yan et al. (5) have also suggested that FcRn-mediated recycling of endogenous IgG in patients with multiple myeloma may shorten the half-life of the therapeutic monoclonal antibody daratumumab. This evidence concerns the gene FCGRT and AL amyloidosis.